Tech Company Financing Transactions
Cortexyme Funding Round
On 1/5/2016, Cortexyme landed $7.9 million in funding from private investors.
Transaction Overview
Company Name
Announced On
1/5/2016
Transaction Type
Venture Equity
Amount
$7,918,642
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 13 investors participated in the offering. Amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
269 East Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Cortexyme (Nasdaq: CRTX) is developing treatments for Alzheimer's and other degenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Casey Lynch
Chief Scientific Officer
Stephen Dominy
Executive Vice President
Leslie Holsinger
VP - Operations
Kristen Gafric
Browse more venture capital transactions:
Prev: 1/5/2016: Pathway Genomics venture capital transaction
Next: 1/5/2016: Cloudability venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs